Retension's $51.75M IPO buys a Phase 2b readout, but trial costs will set the clock
Retension's first earnings report since its upsized October IPO shows a $5.9M quarterly loss and a single catalyst: RTN-001 Phase 2b data in H1 2027. Peers show how thin other routes to capital are.
What happened
On November 18, 2026, Retension Pharmaceuticals (Nasdaq: RTSN) reported third-quarter results and a corporate update. The quarter's net loss was $5.9 million. In October the company closed an upsized Nasdaq IPO with $51.75 million in gross proceeds.
The proceeds support a single program: RTN-001, a PDE5 inhibitor in a roughly 280-patient Phase 2b trial in uncontrolled hypertension. Topline data are expected in the first half of 2027. The company has linked its near-term story to that one readout.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Sources
- Retension Pharmaceuticals posts Q3 2026 results after $51.75M IPO; RTN-001 Phase 2b data due H1 2027 Retension Pharmaceuticals, Inc. · 18 Nov 2026
- ReTo Eco-Solutions reports $4.0M H1 2026 net loss on $963K revenue, after acquisition and private placements ReTo Eco-Solutions, Inc. · 18 Nov 2026
- JIADE LIMITED prices $1.2M registered direct offering of 6.67M shares at $0.18 each JIADE Ltd · 18 Nov 2026
- Insight Molecular Diagnostics prices $15M underwritten public offering of stock and pre-funded warrants Insight Molecular Diagnostics Inc. · 18 Nov 2026
- Navios-linked borrowers sign $90.37M Alpha Bank term loan to fund two 115,000 DWT tankers Navios Maritime Partners L.P. · 18 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Insight Molecular's $15M raise shows how thin the small-cap diagnostics funding market is
IMDX's $1.75-per-share offering, with pre-funded warrants and a transplantation R&D pitch, sits at the small end of a financing spectrum that runs from a $51.75M IPO to royalty sales.
Kyntra's prostate exit shows how thin the funding runway is for a biotech that has to reset
After a Phase 2 interim miss, Kyntra Bio is cutting its royalty-financing cap and pivoting to roxadustat in MDS, and its plan is subject to funding in a split biotech capital market.
Protagenic's $5M Placement Shows the Gap Between Windward's IPO and Microcap Funding
Protagenic's $1.5M upfront, up to $5M milestone-linked raise for PT00114 contrasts with Windward's $251.2M IPO and puts a spotlight on staged, warrant-heavy financing.